Navigation Links
Generic Erosion of Established Agents Will Offset Growth From Uptake of Emerging Therapies in the Market for Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms
Date:8/3/2009

WALTHAM, Mass., Aug. 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, from 2013 to 2018, generic erosion of established agents--most notably tamsulosin--will cause a decline of more than eight percent in the drug market for benign prostatic hyperplasia and male lower urinary tract symptoms in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Generic erosion will offset market growth of more than seven percent that will be driven by the uptake of emerging agents from 2008 to 2013.

The new Pharmacor report entitled Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms finds that the market is saturated with effective, well-established agents. The market is also concentrated as, in 2008, tamsulosin garnered just over half of all major-market sales for benign prostatic hyperplasia. Tamsulosin, the most widely-used alpha blocker for the indication, is marketed by Boehringer Ingelheim as Flomax/Josir/Alna/Pradif/Urolosin and by Astellas as Omix/Omnic/Flomaxtra/Harnal. Generic versions of tamsulosin have been available in Europe and Japan since 2006 and, in the first half of 2010, the drug will be generically available in the United States as well. As a result of generic competition, tamsulosin's annual major-market sales will plummet 41 percent between 2008 and 2013, according to the report.

The report also finds that, while symptom relief remains the primary concern in treating the disease, drug development for benign prostatic hyperplasia has focused on improving dosing convenience and slowing disease progression. Owing to its dosing convenience, GlaxoSmithKline's tamsulosin/dutasteride fixed-dose combination Duodart will likely increase compliance, while Aeterna Zentaris/Sanofi-Aventis/Shionogi's cetrorelix and Aeterna Zentaris/Spectrum Pharmaceuticals/Nippon Kayaku's ozarelix both aim to reduce the size of the prostate and slow disease progression. Additionally, the report finds that drug developers are also focusing on targeting comorbidities, such as erectile dysfunction, with a single agent, namely, Eli Lilly's Cialis.

"If it's approved for the indication, Cialis will be used to treat patients diagnosed with both male lower urinary tract symptoms and erectile dysfunction," said Decision Resources Analyst Benjamin Guikema, Ph.D. "Although we anticipate that, if approved, Cialis would face substantial reimbursement hurdles for the disease through 2018, it has the potential to establish itself as a dominant therapy in the benign prostatic hyperplasia and male lower urinary tract symptoms market if it were to obtain favorable reimbursement in the years after that."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources         Decision Resources, Inc.
    Christopher Comfort        Elizabeth Marshall
    781-296-2597               781-296-2563
    ccomfort@dresources.com    emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
6. Generic prostate drug helps find high-risk cancers early
7. Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory
8. Mylan Vice Chairman and CEO Robert J. Coury to Ring NYSE Closing Bell(R) in Celebration of Merck Generics Acquisition
9. FDA Announces Initiative to Bolster Generic Drug Program
10. FDA Struggles to Keep Pace With Requests for Generics
11. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... 13, 2016 , ... The National Association for Children of ... representing the growing community of recovering individuals (now over 23 million), to issue ... policies addressing addiction. , Although many of the presidential candidates of both ...
(Date:2/13/2016)... FL (PRWEB) , ... February 13, 2016 , ... The ... environmental impact of American businesses. , The increasingly modern world of instantaneous consumption ... often on non-renewable energy sources such as oil and coal, which pollutes our air, ...
(Date:2/13/2016)... ... ... Au Pair comes all the way around the world to provide child care ... often worried things won’t go well. More often than not, however, they find out their ... Year winner’s all commented how their Au Pairs have become a part of the family, ...
(Date:2/12/2016)... ... February 12, 2016 , ... According to an article published ... for a significant portion of hernia repairs throughout the United States. Commenting on this ... Center notes that this trend has not only been expected, but it seems to ...
(Date:2/12/2016)... Seattle, WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens ... technologies for low-resource settings. The partnership will recruit top students from U.S. ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 2016 Indiso ltd ... ungedeckten medizinischen Bedarf bei Lungen- und Atemwegserkrankungen ... Forschungsprogramms bekannt. Das Programm, das sich mit ... respiratorischen Funktionen und anderer klinischer Parameter. ... das sich auf den ungedeckten medizinischen Bedarf ...
(Date:2/11/2016)... - Cardiac Marker Diagnostic ... and Cancer Therapy. - European Point of Care ... - Key Diagnostic Testing Markets. - Molecular ... Genetic Testing. - Molecular Diagnostics in Infectious Disease ... Diagnostic Products World Markets. - Point of Care ...
(Date:2/11/2016)... LONDON , Feb. 11, 2016 Stem ... that are characterized by self-renewal and the capacity to ... a relatively new discovery, as the first mouse embryonic ... it was not until 1995 that the first culturing ... pluripotent stem cells were not produced until 2006 As ...
Breaking Medicine Technology: